Orgenesis (ORGS) AI Stock Analysis

• Market Cap: $315.32K
• Dividend Yield: N/A
• Average Volume (3M): 792.00
• Price to Earnings (P/E): ―
• Beta (1Y): -0.27
• Revenue Growth: -93.57%
• EPS Growth: 54.86%
• Country: US
• Employees: 146
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 5,169,248
• 10 Day Avg. Volume: 889
• 30 Day Avg. Volume: 792
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 117.89
• Enterprise Value/Revenue: 50.64
• Enterprise Value/Gross Profit: -32.41
• Enterprise Value/Ebitda: -1.52
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 29 Underperform
• Price Target: ―

Orgenesis faces substantial financial challenges, with negative revenue and cash flow issues indicating significant instability. Despite negative technical indicators, recent corporate governance improvements may provide a slight strategic advantage. However, these factors are overshadowed by the company's overarching financial distress, resulting in a low overall stock score.

Orgenesis Business Overview & Revenue Model

Company Description

Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.

How the Company Makes Money

Orgenesis makes money primarily through its Point-of-Care (POCare) platform, which enables the localized production of cell and gene therapies. The company partners with healthcare providers, research institutions, and biotech companies to develop and manufacture therapies at or near the point of care. Revenue is generated through licensing agreements, partnerships, and service contracts associated with the POCare platform. Additionally, Orgenesis earns income from proprietary technology solutions and consulting services offered to its partners, facilitating the efficient production of advanced therapies. Strategic collaborations and joint ventures also play a critical role in expanding its market reach and enhancing its revenue potential.

Orgenesis Financial Statement Overview

Summary

Orgenesis exhibits significant financial difficulties across all key areas. The income statement points to operational challenges and declining revenues, the balance sheet indicates financial distress with negative equity, and cash flow statements highlight liquidity problems. These factors collectively suggest a critical need for strategic realignment or external financial support to stabilize the company's financial position.

Income Statement

The income statement shows significant challenges, with negative revenue and declining profit margins. Gross profit margin and net profit margin are deeply negative, indicating severe operational inefficiencies or cost issues. Revenue has drastically decreased over the years, with the latest TTM period showing negative revenue, which is concerning for the company's growth prospects.

Balance Sheet

The balance sheet reveals financial instability, with negative stockholders' equity indicating more liabilities than assets. The debt-to-equity ratio is not meaningful due to negative equity, signaling potential financial distress. The equity ratio is also negative, underscoring the company's leveraged position and financial vulnerability.

Cash Flow

Cash flow analysis indicates negative free cash flow and operating cash flow, suggesting liquidity issues. The free cash flow growth rate is negative, reflecting an inability to generate positive cash flow from operations. The operating cash flow to net income ratio is not favorable, further highlighting cash flow constraints.

Breakdown	TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	734.00K	530.00K	36.02M	35.50M	7.65M	33.26M
Gross Profit	-1.15M	-5.72M	15.59M	7.34M	-22.97M	15.14M
EBITDA	-24.48M	-60.72M	-8.16M	-15.72M	-94.21M	-18.91M
Net Income	-9.55M	-55.36M	-12.17M	-18.06M	-95.13M	-26.04M
Balance Sheet
Total Assets	29.69M	14.55M	90.93M	59.84M	77.68M	92.50M
Cash, Cash Equivalents and Short-Term Investments	204.00K	837.00K	5.31M	5.47M	44.92M	11.39M
Total Debt	17.30M	22.62M	20.27M	11.84M	12.91M	24.78M
Total Liabilities	53.62M	35.53M	31.65M	21.21M	24.96M	86.42M
Stockholders Equity	-23.90M	-20.98M	27.56M	38.49M	52.58M	5.48M
Cash Flow
Free Cash Flow	-15.24M	-16.93M	-37.34M	-34.73M	-79.57M	-25.35M
Operating Cash Flow	-14.98M	-14.84M	-24.92M	-26.87M	-78.05M	-13.22M
Investing Cash Flow	73.00K	-3.71M	-14.13M	-12.38M	105.61M	-13.78M
Financing Cash Flow	14.56M	13.62M	19.58M	-106.00K	5.88M	24.10M

Orgenesis Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.06
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORGS, the sentiment is Negative. The current price of 0.06 is below the 20-day moving average (MA) of 0.51, below the 50-day MA of 0.59, and below the 200-day MA of 1.69, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 45.91 is Neutral, neither overbought nor oversold. The STOCH value of 30.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ORGS.

Orgenesis Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MESO	54 Neutral	2.03B	-20.11	-17.10%	―	192.01%	4.89%
BLUE	51 Neutral	48.67M	-0.24	345.59%	―	127.51%	56.94%
PSTV	48 Neutral	41.25M	-0.19	145.02%	―	-3.49%	27.88%
VERU	47 Neutral	50.86M	-1.78	-116.97%	―	-52.76%	43.40%
FATE	44 Neutral	110.98M	-0.66	-58.44%	―	-31.23%	14.92%
ORGS	29 Underperform	$315.32K	―	183.88%	―	-93.57%	54.86%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Orgenesis Corporate Events

Orgenesis Expands Board with Three New Appointments

The Company’s Board of Directors has expanded from four to seven members with the addition of Adam Pelavin, Jagannathan Bhalaji, and Santhosh Nagaraj, who will serve until the 2025 annual meeting. They will receive stock options and cash retainers under the Non-Employee Director Compensation Policy, enhancing their roles as directors. These appointments align with strategic efforts to bolster the Board’s expertise and governance capabilities, offering potential growth opportunities for the Company.